| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838558 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(6 months ago) | |
| US7834060 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
Mar, 2023
(6 months ago) | |
| US7868044 | GALDERMA LABS LP | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
Mar, 2023
(6 months ago) | |
| US8703820 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Mar, 2023
(6 months ago) | |
| US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(11 months from now) | |
| US7579377 | GALDERMA LABS LP | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Feb, 2025
(1 year, 5 months from now) | |
| US8435502 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
Sep, 2026
(2 years from now) | |
| US8709392 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
Sep, 2026
(2 years from now) | |
| US7998467 | GALDERMA LABS LP | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
May, 2028
(4 years from now) | |
Differin is owned by Galderma Labs Lp.
Differin contains Adapalene.
Differin has a total of 9 drug patents out of which 4 drug patents have expired.
Expired drug patents of Differin are:
- US7838558
- US7834060
- US7868044
- US8703820
Differin was authorised for market use on 19 June, 2007.
Differin is available in gel;topical dosage forms.
Differin can be used as topical treatment of acne vulgaris, treatment of acne.
The generics of Differin are possible to be released after 31 May, 2028.
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: Treatment of acne; Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
DIFFERIN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic